Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus Peer-reviewed article highlights potential treatment for OLP with focus on localized drug deliveryPITTSBURGH, Dec. 03, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical ...

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group PITTSBURGH, November 21, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a lipo ...

PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC). Lipella Pharmaceuticals, a cl ...

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company report ...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth No FDA-approved therapy currently exists for OLP Patient registry and OLP study information is now available Pittsburgh, PA, August 22, 2024 – Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research a ...

Core Insights - Lipella Pharmaceuticals has introduced LP-20, a novel MRI contrast agent aimed at diagnosing interstitial cystitis and detecting bladder cancer, which will be presented at the 5th International Consultation on Interstitial Cystitis Japan [1][3] Group 1: Product Overview - LP-20 is designed to identify bladder permeability defects and is administered via catheter, utilizing advanced MRI technology to aid in the diagnosis of interstitial cystitis and bladder cancer progression [2][4] - The agent has completed preclinical and proof-of-concept human trials, showing potential as a rapid and cost-effective diagnostic solution [2][4] Group 2: Clinical Significance - The use of LP-20 represents a significant advancement in bladder diagnostics, offering a non-invasive alternative to traditional methods such as cystoscopy [4] - The innovative imaging technique addresses unmet needs in urology, potentially enhancing patient care and streamlining patient identification for clinical trials [3][4] Group 3: Company Background - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications, particularly targeting diseases with significant morbidity and mortality [6]

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us," "we" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella's Phase 2a trial is ...

Group 1 - Lipella Pharmaceuticals' stock is experiencing significant gains following an update on its Phase 2a clinical trial for LP-310, aimed at treating Oral Lichen Planus (OLP), a condition affecting over 6 million Americans without an FDA-approved treatment [1][4]. - The CEO of Lipella Pharmaceuticals, Dr. Jonathan Kaufman, expressed satisfaction with the rapid site activation and initial patient enrollment, highlighting this as a crucial milestone for both the company and the patient community [2][4]. - The clinical trial is currently active, with patient recruitment ongoing across multiple sites, indicating progress in the study [4]. Group 2 - The trading volume for LIPO shares has surged, with over 41 million shares traded, compared to a daily average of approximately 46,000 shares [5]. - As of Monday morning, LIPO stock has increased by 145.8%, reflecting strong market interest [6].

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral ...